MCP110| CAS 521310-51-0|DC Chemicals

Cas No.:	521310-51-0
Chemical Name:	N-[[3-Methoxy-4-(phenylmethoxy)phenyl]methyl]-N-[2-(2-pyridinyl)ethyl]benzenepentanamide
Synonyms:	MCP 110
SMILES:	O=C(N(CC1=CC=C(OCC2=CC=CC=C2)C(OC)=C1)CCC3=NC=CC=C3)CCCCC4=CC=CC=C4
Formula:	C₃₃H₃₆N₂O₃
M.Wt:	508.65
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	[1]. Juran Kato-Stankiewicz,et al. Inhibitors of Ras/Raf-1 Interaction Identified by Two-Hybrid Screening Revert Ras-dependent Transformation Phenotypes in Human Cancer Cells. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14398-403.

Description:	MCP110 is an inhibitor of Ras/Raf-1 interaction. MCP110 blocks the interaction of Ras with Raf[1].
Target:	Ras RAF
In Vitro:	MCP110 (10 and 20 uM) inhibits H-Ras (V12)-induced AP-1 activation in HEK293 cells. Ras stimulation of Raf-1 activity is significantly decreased by MCP110 (20 μM) [1]. MCP110 (1, 2, 5, 10, and 20 μM) shows a dose-dependent inhibition of elevated Raf-1 activity in fibrosarcoma HT1080 cells[1]. MCP110 (20 μM) decreases cyclin D level stimulated by the treatment with EGF (100 ng/mL), platelet-derived growth factor (20 ng/mL) , serum, or phorbol 12-myristate 13-acetate (100 nM) in A549 cells[1].
References:	[1]. Juran Kato-Stankiewicz,et al. Inhibitors of Ras/Raf-1 Interaction Identified by Two-Hybrid Screening Revert Ras-dependent Transformation Phenotypes in Human Cancer Cells. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14398-403.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.